3
Jun
2021

Amgen’s KRAS Triumph, Eric Lander in the Saddle, and EQRx Takes Aim at PD-L1

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

The Variant on the Move
Califf Gets FDA Nod, Novo Acquires Dicerna, & a Shrewd Investment in Pittsburgh
Pfizer’s Game-Changer, Moderna-NIH Feud Goes Public, & Genomics England Ends Dx Odysseys
The Vaccine Pile-Up, Regeneron Crushes It, CF Foundation Bets on Flagship Combos